Pathology & Oncology Research

, Volume 19, Issue 1, pp 119–122 | Cite as

Successful Treatment of Solitary Bone Metastasis of Non-Small Cell Lung Cancer with Bevacizumab and Hyperthermia

  • Gábor Rubovszky
  • Tünde Nagy
  • Mária Gődény
  • András Szász
  • István Láng


Non-small cell lung cancer (NSCLC) represents 85 % of all malignant lung cancers. In metastatic disease the principle goal of palliative therapy is to prolong survival with least toxicity and best patients’ quality of life. Bevacizumab (BEV) has been approved as first line treatment in combination with platinum based chemotherapy and maintenance therapy in NSCLC. BEV can be added safely to several chemotherapeutic agents, however there is no data on coadministration with thermotherapy. Even in localized disease no robust evidence exists about the beneficial effect of loco-regional thermotherapy on overall survival, but it might be used successfully in symptom palliation. In this article a successful co-administration of BEV and hyperthermia is reported in a patient with monolocalized bone metastasis from previously operated NSCLC. This case suggests that electrohyperthermia can probably be incorporated in palliative therapy added not only to radiotherapy or chemotherapy but also to anti-angiogenic BEV treatment.


Solitary bone metastases Lung cancer Hyperthermia Bevacizumab 


  1. 1.
    Wakelee HA, Bernardo P, Johnson DH et al (2006) Changes in the natural history of nonsmall cell lung cancer (NSCLC)–comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer 06:2208–2217CrossRefGoogle Scholar
  2. 2.
    Yang P, Allen MS, Aubry MC et al (2005) Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 28:452–462CrossRefGoogle Scholar
  3. 3.
    Govindan R, Page N, Morgensztern D et al (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539–4544PubMedCrossRefGoogle Scholar
  4. 4.
    Azzoli CG, Baker S, Temin S et al (2009) American Society of Clinical Oncology Clinical Practice guideline update on chemotherapy for Stage IV non-Nmall-Cell Lung Cancer. J Clin Oncol 27:6251–6266PubMedCrossRefGoogle Scholar
  5. 5.
    Sandler A, Gray R, Perry MC (2006) Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550PubMedCrossRefGoogle Scholar
  6. 6.
    Reck M, von Pawel J, Zatloukal P (2009) Phase iii trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: avail. J Clin Oncol 27:1227–1234PubMedCrossRefGoogle Scholar
  7. 7.
    Laskin J, Crinò L, Tsai C (2009) MO19390 (SAIL): first-line bevacizumab-based therapy in advanced non-small cell lung cancer (nsclc)—outcome by chemotherapy regimen [abstract C2.5]. J Thorac Oncol 4(Suppl 1):S359Google Scholar
  8. 8.
    Hirsh V (2008) Emerging safety data for bevacizumab in advanced non–small-cell lung cancer. Clin Lung Cancer 9(suppl 2):S62–S70PubMedCrossRefGoogle Scholar
  9. 9.
    Crinò L, Mezger J, Griesinger F et al (2009) MO19390 (SAIL): safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (nsclc) [abstract 8043] Proc Am Soc. Clin Oncol 27:417sGoogle Scholar
  10. 10.
    Fischbach N, Spigel D, Brahmer J, on behalf of the ARIES investigators (2009) Preliminary safety and effectiveness of bevacizumab (bv) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (nsclc) from the aries study: a bevacizumab (bv) treatment observational cohort study (ocs) [abstract 8040]. Proc Am Soc Clin Oncol 27:416sGoogle Scholar
  11. 11.
    Mezger J, von Pawel J, Reck M (2009) Bevacizumab (Bv) single-agent maintenance following Bv-based chemotherapy in patients with advanced non-small cell lung cancer (nsclc): results from an exploratory analysis of the avail study [abstract e19001] Proc Am Soc. Clin Oncol 27:e19001Google Scholar
  12. 12.
    Miller V, O’Connor P, Soh C, on behalf of the ATLAS Investigators (2009) A randomized, double-blind, placebo-controlled, phase iiib trial (atlas) comparing bevacizumab (b) therapy with or without erlotinib (e) after completion of chemotherapy with b for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (nsclc) [abstract LBA8002] Proc Am Soc. Clin Oncol 27:799sCrossRefGoogle Scholar
  13. 13.
    Hildebrandt B, Wust P, Ahlers O et al (2002) The cellular and molecular basis of hyperthermia. Clin Rev Oncol Haemat 43:33–56CrossRefGoogle Scholar
  14. 14.
    Jiang Z, Yan W, Ming J et al (2007) Docetaxel weekly regimen in conjunction with RF hyperthermia for pretreated locally advanced non-small cell lung cancer: a preliminary study. BMC Cancer 7:189PubMedCrossRefGoogle Scholar
  15. 15.
    Shen H, Li XD, Wu CP et al (2011) The regimen of gemcitabine and cisplatin combined with radio frequency hyperthermia for advanced non-small cell lung cancer: a phase II study. Int J Hyperthermia 27:27–32PubMedCrossRefGoogle Scholar
  16. 16.
    Mitsumori M, Zeng ZF, Oliynychenko P et al (2007) Regional hyperthermia combined with radiotherapy for locally advanced non-small cell lung cancers: a multi-institutional prospective randomized trial of the International Atomic Energy Agency. Int J Clin Oncol 12:192–198PubMedCrossRefGoogle Scholar
  17. 17.
    Moon SD, Ohguri T, Imada H et al (2011) Definitive radiotherapy plus regional hyperthermia with or without chemotherapy for superior sulcus tumors: a 20-year, single center experience. Lung Cancer 71:338–343PubMedCrossRefGoogle Scholar
  18. 18.
    Sumiyoshi K, Strebel FR, Rowe RW et al (2003) The effect of whole-body hyperthermia combined with ‘metronomic’ chemotherapy on rat mammary adenocarcinoma metastases. Int J Hyperthermia 19:103–118PubMedCrossRefGoogle Scholar
  19. 19.
    Hermisson M, Weller M (2000) Hyperthermia enhanced chemosensitivity of human malignant glioma cells. Anticancer Res 20(3A):1819–1823PubMedGoogle Scholar
  20. 20.
    Szasz A, Szasz N, Szasz O (2010) Oncothermia –principles and practices. Springer Verlag, HeidelbergGoogle Scholar
  21. 21.
    Chun-Yi L, Yiing-Feng H, Hua-Tzu H et al (2009) Lung cancer with solitary bone metastasis in the radius. Clin Nucl Med 34:684–685PubMedCrossRefGoogle Scholar
  22. 22.
    Shih WJ, Magoun S, Lahar B et al (1998) An unusual case of a tibial metastasis as the clinical presentation of bronchogenic adenocarcinoma. J Nucl Med Technol 26:91–93PubMedGoogle Scholar
  23. 23.
    An SJ, Huang YS, Chen ZH (2011) et al. Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy, Med Oncol [Epub ahead of print]Google Scholar
  24. 24.
    Horn L, Dahlberg SE, Sandler AB et al (2009) Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 27:6006–6011PubMedCrossRefGoogle Scholar
  25. 25.
    Herbst RS, Ansari R, Bustin F et al (2011) Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 377:1846–1854PubMedCrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2012

Authors and Affiliations

  • Gábor Rubovszky
    • 1
  • Tünde Nagy
    • 1
  • Mária Gődény
    • 1
  • András Szász
    • 2
  • István Láng
    • 1
  1. 1.National Institute of OncologyBudapestHungary
  2. 2.Biotechnics DepartmentSzt. István UniversityGödöllőHungary

Personalised recommendations